drugset / Trial / NCT04714619
CB-103 Plus NSAI In Luminal Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Multicenter, single-arm, open label, phase II clinical trial with safety run-in to evaluate the safety, tolerability, pharmacokinetics and efficacy of CB-103 in combination with a non-steroidal aromatase inhibitor (NSAI), anastrozole or letrozole, in Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer patients who have achieved clinical benefit during prior NSAI-based treatment.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2021-09-02
- Completion
- 2022-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LIMANTRAFIN | Small molecule | — | Oral |
| Background | Anastrozole | Other / unclassified | — | Oral |
| Background | Letrozole | Other / unclassified | — | Oral |